This Month in Ovarian Cancer

October was a busy, wide-ranging month for ovarian cancer research. The strongest threads came from people living with the disease: a large quality-of-life analysis showed that adding olaparib maintenance did not make people feel worse, long-term results confirmed durable benefit from a targeted pill combination for low-grade serous ovarian cancer, and new reviews mapped out how to choose among the growing list of treatments for platinum-resistant disease. Researchers also looked hard at prevention and risk, from how surgeons handle risk-reducing surgery around the world to what the evidence on talc really shows. Alongside that came steady progress on earlier detection with blood-based tests, and a clear-eyed look at the gaps in survival and clinical trial access that still separate communities.

The papers highlighted here represent a selection of those published during the month. The papers were selected and summarized by AI. Accuracy of the summaries was confirmed by a scientist. This digest incorporates only open-access research articles that are free to be read by the entire community and that are explicitly licensed to be shared and reused.

PARP inhibitors and HRD testing are being refined to match the right treatment to the right person

PARP inhibitors, targeted treatments that block cancer cells' ability to repair their own DNA, are now a standard maintenance option after first-line chemotherapy. They work best when tumors have homologous recombination deficiency (HRD), meaning a weakened DNA repair system, often caused by a BRCA mutation, a gene change affecting DNA repair. This month's research sharpened the picture of who benefits most and how it feels to take them.

• If you are considering maintenance olaparib with bevacizumab, this analysis is reassuring about how you are likely to feel day to day. A review of quality-of-life questionnaires from 806 participants in the phase III PAOLA-1 trial and found no meaningful worsening of overall quality of life from adding olaparib, with a delay in quality-of-life decline among people whose tumors were HRD-positive. After the cancer progressed, emotional and social well-being dropped noticeably, a reminder that support matters most at that point. (Read the full paper)

• Which DNA repair gene is altered may change how much a PARP inhibitor helps. In 50 people at McGill University Health Centre who received PARP inhibitor maintenance, 34% of those with BRCA1 mutations were free of progression at two years, compared with 71% with BRCA2 mutations and 77% with mutations in other repair genes such as RAD51C or RAD51D. The study was retrospective and small, so it raises a question to discuss with your team rather than a firm answer. (Read the full paper)

• PARP inhibitors may help some people whose tumors lack an inherited BRCA mutation but still have repair defects. In a phase II trial at the University of Sydney, 40% of people with platinum-sensitive relapsed high-grade serous ovarian cancer whose tumors had a silenced BRCA1 or RAD51C gene, or a mutation in another repair gene, responded to olaparib. The trial was small (15 ovarian cancer participants), but it supports broader tumor testing. (Read the full paper)

• Current HRD tests capture only a snapshot, and researchers are looking for ways to track response as it happens. A narrative review from Shaanxi Provincial Cancer Hospital describes complementary tests, including RAD51 staining of tumor tissue and KELIM, a score based on how quickly CA-125 falls during early chemotherapy, that could help predict who will benefit from a PARP inhibitor. Most of these tools still need validation before routine use. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

New options are widening care for platinum-resistant and recurrent disease

When ovarian cancer comes back within six months of platinum chemotherapy (platinum-resistant disease), options have historically been limited. That is changing, with immunotherapy, antibody-drug conjugates (ADCs, antibodies that carry a chemotherapy payload directly to cancer cells), and new combinations now in the mix. This month's research helps put those options in order and is honest about what has not worked.

• If you are facing platinum-resistant disease, there are now more evidence-based choices, and the order matters. A review of recent phase III results, including pembrolizumab with weekly paclitaxel (KEYNOTE-B96), mirvetuximab soravtansine for tumors with high folate receptor alpha (MIRASOL), and relacorilant with nab-paclitaxel (ROSELLA), proposed a framework for sequencing treatments based on biomarkers, prior side effects, financial burden, and priorities. (Read the full paper)

• Eye side effects remain the most important safety issue to watch with mirvetuximab soravtansine, an ADC targeting folate receptor alpha. Analyzing 1,249 real-world reports to the US Food and Drug Administration's adverse event database, researchers found eye disorders were the most frequently reported problems, with blurred vision, keratitis, and keratopathy (inflammation and damage to the cornea) standing out, along with a signal for pneumonitis (lung inflammation). Regular eye checks during treatment remain essential. (Read the full paper)

• A personalized cell therapy is showing early promise. In a pilot study at Copenhagen University Hospital Herlev, five people with platinum-resistant ovarian cancer received tumor-infiltrating lymphocyte (TIL) therapy, which grows a patient's own tumor-fighting immune cells and returns them in large numbers, along with drugs blocking the PD-1 and LAG-3 immune brakes. Tumors shrank in four of the five, and the treatment was considered safe, but larger studies are needed. (Read the full paper)

• Not every promising idea pans out, and negative results help steer research. In the phase II PARAGON-II trial, 32 people with hormone receptor-positive, platinum-resistant ovarian cancer received letrozole (a hormone therapy) with ribociclib (a drug that blocks cell-division proteins called CDK4 and CDK6); only one person's tumor shrank, and median time before progression was 1.9 months. The investigators also found that significant abdominal symptoms at the start of treatment were linked with shorter survival. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Surgical quality still shapes survival, and new tools aim to make surgery safer

Surgery to remove all visible cancer remains one of the most powerful tools in advanced ovarian cancer. This month's research looked at how well that goal is met in routine care and how surgical risk is predicted.

• Complete removal of visible disease continues to matter for survival outside specialist trials. In a registry study of 576 people with advanced ovarian cancer in Hamburg, Germany, surgeons removed all visible cancer in 64.2% of patients, and those patients had a 38% lower risk of death. The authors note this is achievable in routine practice but opportunities for improvement remain at non-specialized centers, which supports asking about your surgical team's experience. (Read the full paper)

• Tools that predict surgical complications are common but uneven in quality. A systematic review found 28 studies of prediction models for gynecologic cancer surgery, with accuracy ranging widely and few models properly checked for reliability. Better-tested tools could help you and your surgeon weigh the risks of an operation more precisely. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Hereditary risk and prevention decisions are becoming more personalized

For people with inherited risk, prevention choices are deeply personal. This month's research examined how surgeons handle risk-reducing surgery, which genetic variants change recommendations, and what the evidence on talc shows.

• Whether the uterus is removed at the same time as the ovaries and fallopian tubes (risk-reducing salpingo-oophorectomy) depends heavily on where you live. Among 2,181 BRCA1 and BRCA2 carriers, concurrent hysterectomy was performed in 48.8% in the Americas, 14.2% in Australia, and 2.8% in Europe. Interviews with providers in 12 countries showed little agreement on when it is needed, so it is worth asking your surgeon what is recommended for you and why. (Read the full paper)

• Genes aside from BRCA1 and BRCA2 can also raise risk, and recommendations differ by gene. Reviewing genetic testing for 3,416 people at a specialized hereditary breast and ovarian cancer center in Erlangen, Germany, researchers found CHEK2 and ATM were the most common moderate-risk genes, while ovary and tube removal was mainly discussed with people carrying RAD51C or RAD51D variants. If you carry a moderate-risk variant, a genetic counselor can help clarify your options. (Read the full paper)

• The evidence on talc and ovarian cancer remains a concern but is of limited quality. An umbrella review pooled nine systematic reviews and found that four of five reviews on cosmetic talc reported a higher ovarian cancer risk, although confidence in most of the reviews was rated low or critically low. Avoiding genital talc use is a simple precaution while better evidence accumulates. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Researchers are building better ways to find ovarian cancer earlier and tell tumor types apart

Ovarian cancer is often found late because early symptoms are vague and there is no proven screening test. This month's studies tested better ways to judge whether a pelvic mass is cancer and explored blood-based tests.

• If you have an ovarian mass found on ultrasound, structured scoring tools can help decide whether you need a specialist referral. In 966 patients across Danish hospitals and clinics, researchers found that the IOTA ADNEX model, an ultrasound-based risk calculator, was at least as good as the older Risk of Malignancy Index at ruling out cancer, and they proposed a referral threshold that balances catching cancers with avoiding unnecessary referrals. (Read the full paper)

• A liquid biopsy, a blood test that detects signs of cancer in the bloodstream, may become more accurate by reading fats carried in tiny particles called extracellular vesicles. A panel of these lipids, combined with CA-125, distinguished ovarian cancer from benign masses with very high accuracy in a verification group. This is early-stage work that needs larger studies. (Read the full paper)

• Ultrasound images may hold information that helps tell high-grade from low-grade serous cancer before surgery. In a pilot study of 153 patients at Fondazione Policlinico Universitario A. Gemelli in Rome, radiomics (computer analysis of image patterns invisible to the eye) was used to build models separating the two types, which are treated differently. The findings need external validation. (Read the full paper)

• Extracellular vesicles are attracting attention as a liquid biopsy target, but hurdles remain. A review from the University of L'Aquila and Italy's National Research Council explains how vesicle cargo reflects tumor behavior and treatment resistance, and why variability in methods and a lack of large validation studies still stand between this science and the clinic. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Rare ovarian cancer types are getting more targeted attention

Low-grade serous, sex cord stromal, and other less common ovarian cancers behave differently from the more common high-grade serous type and often need different care. This month brought longer-term trial data and new guidance.

• For recurrent low-grade serous ovarian cancer, the oral combination of avutometinib (which blocks the RAF and MEK growth signals) and defactinib (which blocks a protein called FAK) continues to deliver lasting responses. With about two years of follow-up of 115 patients in the phase II RAMP 201 study, responses lasted a median of 31.1 months, with median time before progression of 19.6 months for tumors with a KRAS mutation and 12.7 months without. Only 12% stopped because of side effects. (Read the full paper)

• Children and adolescents with ovarian sex cord stromal tumors now have European standard-of-care guidance. The European Cooperative Study Group for Paediatric Rare Tumours recommends complete removal of the tumor without spillage, risk-based decisions about chemotherapy, central pathology review, genetic testing, and care within specialist networks. (Read the full paper)

• Low-grade serous cancer can appear decades after a borderline tumor, and molecular testing can guide treatment. Investigators at Brigham and Women's Hospital described a patient whose low-grade serous cancer appeared 35 years after her last surgery for a borderline tumor; the same gene mutation in both tumors pointed to a shared origin and to a targeted therapy that worked quickly. It underlines the value of long-term follow-up and tumor testing. (Read the full paper)

• Cancer starting in the fallopian tube can occasionally be mistaken for an ectopic pregnancy. A case report from the Affiliated Hospital of Jiangsu University describes a 29-year-old with primary tubal choriocarcinoma, a rare pregnancy-related cancer, that was confirmed only after surgery; she reached sustained remission with chemotherapy. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Support, communication, and nursing care matter throughout treatment

Living with ovarian cancer involves much more than treatment decisions. This month's research highlighted what people need from their care teams and how nursing support can help.

• Personalized support from specialist nurses by phone or video can improve well-being. In an evaluation of a national nurse-led telehealth program at Queensland University of Technology, 112 participants reported high levels of fatigue, anxiety, and fear of recurrence at the start; over 12 months, overall well-being and satisfaction with information improved, and people valued being seen and heard as a whole person. (Read the full paper)

• People with advanced gynecologic cancer want clinicians to see them as people, not only as patients. In interviews with 21 patients (17 with ovarian cancer) in the Netherlands, researchers found three needs: being recognized as a person, being involved in decisions the way they prefer, and getting help navigating the health system. Many hesitated to raise non-medical concerns, so it can help to bring those up directly with your team. (Read the full paper)

• Nurses are calling for clearer guidance on specialized gynecologic cancer nursing. In a survey of 72 Australian gynecologic cancer nurses and service leaders, 90% supported developing a dedicated guidance resource, and two-thirds said they would use it weekly. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Epidemiology, access, and health disparities research shows where gaps remain

Where you live and who you are can still shape your outcomes and your access to new treatments. This month's research documented those gaps across racial and ethnic groups and communities.

• Survival gaps by race and ethnicity persist even after accounting for stage and tumor type. In data from 18 Ovarian Cancer Association Consortium studies, Native Hawaiian and Pacific Islander women had a 58% higher risk of death and non-Hispanic Black women a 31% higher risk than non-Hispanic White women, with the gap largest for Native Hawaiian and Pacific Islander women with high-grade serous cancer. Separating out these groups is an important step toward targeted solutions. (Read the full paper)

• Access to clinical trials is not evenly shared. Researchers at Ohio State University linked 70,486 ovarian cancer cases to trial locations and found that people living in the most socially vulnerable US counties had substantially lower odds of having a trial available nearby. Expanding trial sites into these communities is a practical fix. (Read the full paper)

• The COVID-19 pandemic briefly reduced ovarian cancer diagnoses but did not measurably change short-term survival. In a national SEER cancer registry analysis, new ovarian cancer diagnoses fell 6.5% in 2020, but stage at diagnosis, time to treatment, and 18-month cancer-specific survival were similar to pre-pandemic years. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

General and basic-science research continues to probe how ovarian tumors grow and resist treatment

Laboratory, computational, and early drug-development studies explore how ovarian tumors grow, evade the immune system, and resist treatment. None of this work changes care today, but it is listed in the citations so researchers can find it.

Check the citations section for a comprehensive list of publications associated with this topic.

What Does This Mean for Me?

If you are on, or considering, PARP inhibitor maintenance: This month's data suggest olaparib maintenance does not worsen how you feel overall, and that the specific gene involved (BRCA1, BRCA2, or another repair gene) may shape how much benefit you get. Ask your care team: "What did my tumor and germline testing show, and how does that affect my maintenance options?"

If your cancer has come back or is platinum-resistant: There are more options than a few years ago, including immunotherapy combinations and antibody-drug conjugates, and the order you receive them matters. If you are on mirvetuximab, keep up with eye exams and report vision changes promptly. Ask: "Which of the newer treatments am I eligible for, and is there a clinical trial that fits me?"

If you carry a BRCA or other inherited variant: Recommendations depend on the specific gene, and practices such as removing the uterus during risk-reducing surgery vary widely around the world. A genetic counselor and a gynecologic oncologist can help you weigh what is right for you. Clinical trials, including those testing new detection and prevention approaches, are an important way to move the field forward; ask your care team or search ClinicalTrials.gov to learn what is available, and OCRA's patient support resources can help you find community and information.

This digest is prepared by OCRA (Ovarian Cancer Research Alliance) for patients, caregivers, and advocates. It is intended to inform, not to guide individual treatment decisions. Please speak with your care team about what research findings may mean for your specific situation.

Sources

The citations below are grouped to match the sections above. "Directly referenced" papers are the ones summarized in that section; the remaining entries are on-topic papers either not discussed above or behind access restrictions.

PARP inhibitors and HRD testing are being refined to match the right treatment to the right person

Directly referenced:

1. Joly F, et al. "Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)." J Natl Cancer Inst. October 1, 2026. PMID 42033030. https://doi.org/10.1093/jnci/djag122

2. Zeng X, et al. "The Impact of Pathogenic Variants of BRCA1, BRCA2, and other DNA-Repair Genes on the Survival Benefits Conferred by PARP Inhibitors-Single-Centre Experience from Quebec." J Obstet Gynaecol Can. October 2026. PMID 42398909. https://doi.org/10.1016/j.jogc.2026.103447

3. Sjoquist KM, et al. "Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial." Br J Cancer. October 2026. PMID 42420629. https://doi.org/10.1038/s41416-026-03535-6

4. Wu T, et al. "Functional biomarkers complementing static BRCA/HRD testing for dynamic PARP inhibitor therapy in ovarian cancer: a narrative review." Front Oncol. October 13, 2026. PMID 42948144. https://doi.org/10.3389/fonc.2026.1989686

Additional open-access citations:

5. Guan M, et al. "Correlation between BRCA mutational status and lymph node metastasis in advanced epithelial ovarian cancer: a retrospective study." PeerJ. October 20, 2026. PMID 42921539. https://doi.org/10.7717/peerj.21823 (BRCA status and lymph node spread)

6. Aubuchon LN, et al. "Endogenous replication stress creates a unique therapeutic window for ALC1 targeting." EMBO Rep. October 19, 2026. PMID 42897309. https://doi.org/10.1038/s44319-026-00966-3 (ALC1 targeting and replication stress, preclinical)

7. Wu CI, et al. "HRDPath: an explainable multi-model deep learning architecture for predicting homologous recombination deficiency from histopathology images." Nat Commun. October 21, 2026. PMID 42907492. https://doi.org/10.1038/s41467-026-78430-y (deep learning HRD prediction from pathology slides)

8. Mu Q, et al. "Inhibition of LncRNA THUMPD3-AS1 enhances olaparib-induced autophagy in BRCA mutant ovarian cancer cells via PI3K pathway." Cell Signal. October 2026. PMID 42259465. https://doi.org/10.1016/j.cellsig.2026.112662 (lncRNA and olaparib-induced autophagy, preclinical)

9. Xi Q, et al. "Targeting G2/M checkpoint vulnerability in homologous recombination-proficient tumors: lessons from ovarian cancer models." Cell Cycle. October 27, 2026. PMID 42947311. https://doi.org/10.1080/15384101.2026.2751743 (G2/M checkpoint targeting in HR-proficient tumors)

10. Zhang S, et al. "Targeting the MAT2A-SAM axis increases platinum sensitivity in ovarian cancer by impairing DNA repair and stemness." bioRxiv. October 13, 2026. PMID 42892768. https://doi.org/10.64898/2026.09.22.753550 (MAT2A targeting and platinum sensitivity, preprint)

Related citations, access restricted:

11. Jo A, et al. "Benefits of PARP inhibitor rechallenge in patients with platinum-sensitive recurrent ovarian cancer previously treated with a PARP inhibitor: a multicenter retrospective study." Int J Clin Oncol. October 2026. PMID 42566090. https://doi.org/10.1007/s10147-026-03056-5 (subscription access)

12. Vergote I, et al. "Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial." Lancet Oncol. October 2026. PMID 42705254. https://doi.org/10.1016/S1470-2045(26)00223-8 (subscription access)

13. Kojo S, et al. "CT imaging features as predictors of homologous recombination deficiency and prognosis in high-grade serous ovarian cancer." Abdom Radiol (NY). October 2026. PMID 41981272. https://doi.org/10.1007/s00261-026-05459-4 (restricted license, CC BY-NC-ND 4.0)

14. McKenna J, et al. "Exploring patient and clinician perspectives for homologous recombination deficient (HRD) biomarker testing to guide precision medicine for advanced ovarian cancer treatment: A qualitative study." Patient Educ Couns. October 10, 2026. PMID 42880199. https://doi.org/10.1016/j.pec.2026.110342 (restricted license, CC BY-NC-ND 4.0)

15. Simcock B, et al. "Molecular profiling of ovarian cancer is feasible and provides valuable therapeutic and research information to women in Aotearoa New Zealand." N Z Med J. October 23, 2026. PMID 42912973. https://doi.org/10.26635/6965.7288 (subscription access)

16. Matheu G, et al. "Morphological and molecular characterization of epithelial ovarian cancer: SEOM-SEAP consensus guidelines for biomarker integration in clinical practice." Clin Transl Oncol. October 2026. PMID 42118479. https://doi.org/10.1007/s12094-026-04335-3 (restricted license, CC BY-NC-ND 4.0)

17. Liu D, et al. "Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial." Lancet Oncol. October 7, 2026. PMID 42843394. https://doi.org/10.1016/S1470-2045(26)00387-6 (subscription access)

18. Harano K, et al. "Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study." Clin Cancer Res. October 15, 2026. PMID 42531373. https://doi.org/10.1158/1078-0432.CCR-25-4887 (subscription access)

19. Zuo J, et al. "Niraparib treatment patterns and outcomes in first-line maintenance therapy for ovarian cancer: The RENI-1 study." Chin Med J (Engl). October 2026. PMID 42343699. https://doi.org/10.1097/CM9.0000000000004165 (restricted license, CC BY-NC-ND 4.0)

20. Su L, et al. "Progression-free survival and overall survival in the first-line treatment of BRCA wild-type advanced epithelial ovarian cancer: An analysis of patient-level data pooled from historical clinical trials." Cancer. October 1, 2026. PMID 42804616. https://doi.org/10.1002/cncr.70630 (subscription access)

21. Saito H, et al. "Radiogenomic Analysis of Contrast-Enhanced MRI for Predicting Pathogenic BRCA Variants in Ovarian Cancer." Acta Med Okayama. October 2026. PMID 42934929. https://doi.org/10.18926/AMO/71341 (license unconfirmed)

22. Cheng K, et al. "Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance." Cancer Res. October 2, 2026. PMID 42467549. https://doi.org/10.1158/0008-5472.CAN-26-0834 (free to read, no reuse license)

New options are widening care for platinum-resistant and recurrent disease

Directly referenced:

23. Mabuchi S, et al. "A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies." Curr Oncol. October 15, 2026. PMID 42930189. https://doi.org/10.3390/curroncol33100622

24. Cui Z, et al. "Real-World Safety Profile of Mirvetuximab Soravtansine: A Population-Based Pharmacovigilance Study Leveraging FAERS and EudraVigilance Databases." Clin Ther. October 27, 2026. PMID 42946592. https://doi.org/10.1016/j.clinthera.2026.09.015

25. Monberg TJ, et al. "Tumor Infiltrating Lymphocyte Therapy Combined With PD-1/LAG-3 Inhibition in Patients With Recurrent Platinum-Resistant Ovarian Cancer." Int J Cancer. October 2026. PMID 42026768. https://doi.org/10.1002/ijc.70510

26. Lee CK, et al. "PARAGON-II cohort C: a phase II basket study of letrozole plus ribociclib in hormone receptor-positive, platinum-resistant, high-grade epithelial ovarian cancer." Int J Gynecol Cancer. October 3, 2026. PMID 42844146. https://doi.org/10.1016/j.ijgc.2026.105600

Additional open-access citations:

27. Anwer K, et al. "Bench-to-Bedside Development of IMNN-001: A Non-Viral IL-12 Gene Therapy for Advanced Ovarian Cancer." Pharmaceutics. October 1, 2026. PMID 42942783. https://doi.org/10.3390/pharmaceutics18101250 (IL-12 gene therapy IMNN-001 development review)

28. Villatoro A, et al. "Combining TAG-72CAR with anti-MUC16CAR improves the potency of ovarian cancer treatment." FEBS J. October 6, 2026. PMID 42834815. https://doi.org/10.1111/febs.70760 (dual-target CAR-T against TAG-72 and MUC16, preclinical)

29. Li DM, et al. "Functional single-cell omics in gynecological cancers immunotherapy: from heterogeneity dissection to clinical translation." Front Immunol. October 12, 2026. PMID 42936408. https://doi.org/10.3389/fimmu.2026.1981010 (single-cell omics in gynecologic cancer immunotherapy, review)

30. Velasquez J, et al. "How slow should we go? Variation and outcomes of steroid tapering for immunotherapy-related toxicities in gynecologic cancer." Gynecol Oncol. October 20, 2026. PMID 42900968. https://doi.org/10.1016/j.ygyno.2026.10.012 (steroid tapering for immunotherapy side effects in gynecologic cancers)

31. Knoedler L, et al. "Low-affinity anti-HER2-CAR T cells efficiently eradicate HER2and HER2cancer cells with reduced toxicity on healthy tissue." Front Bioeng Biotechnol. October 12, 2026. PMID 42936178. https://doi.org/10.3389/fbioe.2026.1895507 (low-affinity HER2 CAR-T, preclinical)

32. Lu G, et al. "Near-Infrared Light-Responsive Liposomes for Modulating Switchable CAR-T Cell Therapy." Int J Nanomedicine. October 26, 2026. PMID 42965079. https://doi.org/10.2147/IJN.S630008 (light-controlled switchable CAR-T, preclinical)

33. Tang X, et al. "Ovarian Cancer Nanovaccines: Recent Strategic Advances from Antigen Selection to Carrier Design." Int J Nanomedicine. October 22, 2026. PMID 42936686. https://doi.org/10.2147/IJN.S642296 (nanovaccine strategies, review)

34. Jin Y, et al. "Stimulator of Interferon Genes (STING) Agonist-Loaded Copper-Based Nanoparticles for B7-H3 Blockade-Enhanced Chemodynamic-Immunotherapy of Ovarian Cancer." Int J Nanomedicine. October 10, 2026. PMID 42877886. https://doi.org/10.2147/IJN.S640431 (STING agonist nanoparticles with B7-H3 blockade, preclinical)

35. Yin X, et al. "Synergistic antitumor effects of combined pembrolizumab and anlotinib via EGFR inhibition and tumor microenvironment remodeling in high-grade serous ovarian cancer." Front Oncol. October 19, 2026. PMID 42973729. https://doi.org/10.3389/fonc.2026.1880902 (pembrolizumab with anlotinib, preclinical models)

36. Chen HH, et al. "The cGAS-STING pathway in ovarian cancer: from genomic instability to immunotherapeutic vulnerability." Front Immunol. October 5, 2026. PMID 42898967. https://doi.org/10.3389/fimmu.2026.1977503 (cGAS-STING pathway review)

37. Mori Y, et al. "Tissue Factor-High Ovarian Clear Cell Carcinoma Shows Immune-Cold Features and Preclinical Activity of Tisotumab Vedotin." Cancer Sci. October 2026. PMID 42437863. https://doi.org/10.1111/cas.70472 (tissue factor-high clear cell carcinoma and tisotumab vedotin, preclinical)

Related citations, access restricted:

38. Edwards CC, et al. "A phase II study in newly diagnosed stage III/IV epithelial ovarian cancer evaluating carboplatin/taxol/pembrolizumab in patients receiving neoadjuvant chemotherapy followed by pembrolizumab maintenance with or without olaparib." Gynecol Oncol. October 2026. PMID 42767168. https://doi.org/10.1016/j.ygyno.2026.09.002 (subscription access)

39. Wu T, et al. "Beyond the "cold" barrier: Redefining the clinical paradigm of immune checkpoint inhibitor therapy in ovarian cancer." Crit Rev Oncol Hematol. October 2026. PMID 42362076. https://doi.org/10.1016/j.critrevonc.2026.105459 (subscription access)

40. Shrestha P, et al. "CD44-Targeted Antibody-Drug Conjugates Suppress Ovarian Tumor Progression and Remodels Cancer Stem Cell-Associated Molecular Programs." Adv Healthc Mater. October 26, 2026. PMID 42935031. https://doi.org/10.1002/adhm.71897 (subscription access)

41. Li T, et al. "Clinical evaluation of bevacizumab intravenous infusion-associated bleeding risk and vascular stress under a vascular‑protective management pathway in recurrent ovarian cancer." Pak J Pharm Sci. October 1, 2026. PMID 42489315. https://doi.org/10.36721/PJPS.2026.39.10.300.1 (license unconfirmed)

42. Takatori E, et al. "Clinical outcomes of 5-day administration of topotecan combined with bevacizumab for platinum-resistant ovarian cancer: a multicenter retrospective analysis." Int J Clin Oncol. October 31, 2026. PMID 42965782. https://doi.org/10.1007/s10147-026-03229-2 (subscription access)

43. Hassan A, et al. "Comparison of carboplatin doses according to several formulae in a cohort of patients treated for an ovarian cancer in real life." J Oncol Pharm Pract. October 2026. PMID 40239094. https://doi.org/10.1177/10781552251332600 (subscription access)

44. Jiang C, et al. "Current status and prospects of chemotherapy-free strategies in ovarian cancer." Crit Rev Oncol Hematol. October 2026. PMID 42468792. https://doi.org/10.1016/j.critrevonc.2026.105492 (restricted license, CC BY-NC-ND 4.0)

45. Wenham RM, et al. "Farletuzumab ecteribulin, a folate receptor alpha (FRα) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1/2 dose-finding study." Gynecol Oncol. October 5, 2026. PMID 42833056. https://doi.org/10.1016/j.ygyno.2026.08.023 (restricted license, CC BY-NC-ND 4.0)

46. Krivenko O, et al. "HER2-directed therapy with Trastuzumab deruxtecan in recurrent mucinous ovarian carcinoma: complete clinical response and response to rechallenge." Gynecol Oncol Rep. October 2026. PMID 42781458. https://doi.org/10.1016/j.gore.2026.102205 (restricted license, CC BY-NC-ND 4.0)

47. Giudice E, et al. "Immune checkpoint inhibitors in platinum-resistant ovarian cancer: Clinical disappointments, biological lessons, and the reopening of therapeutic opportunities." Cancer Treat Rev. October 24, 2026. PMID 42945772. https://doi.org/10.1016/j.ctrv.2026.103237 (subscription access)

48. Sellars MC, et al. "Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial." Nat Med. October 14, 2026. PMID 42875558. https://doi.org/10.1038/s41591-026-04717-8 (subscription access)

49. Tewari KS. "Platinum resistant ovarian cancer - No longer a graveyard for drug development." Gynecol Oncol. October 8, 2026. PMID 42854531. https://doi.org/10.1016/j.ygyno.2026.09.015 (subscription access)

50. Smith G, et al. "Real-world clinical efficacy of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in heavily pretreated platinum-resistant ovarian cancer." Gynecol Oncol. October 1, 2026. PMID 42822082. https://doi.org/10.1016/j.ygyno.2026.09.017 (subscription access)

51. Jones AV, et al. "Real-world outcomes after Mirvetuximab Soravtansine treatment for recurrent ovarian Cancer: Results from a university setting." Gynecol Oncol Rep. October 2026. PMID 42733650. https://doi.org/10.1016/j.gore.2026.102197 (restricted license, CC BY-NC-ND 4.0)

52. Ray-Coquard I, et al. "Sofetabart mipitecan, an antibody drug conjugate targeting folate receptor alpha, in high grade ovarian cancer: Results from the first-in-human phase 1 study." Ann Oncol. October 8, 2026. PMID 42849725. https://doi.org/10.1016/j.annonc.2026.10.001 (subscription access)

53. Lesnock JL, et al. "Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0." J Clin Oncol. October 2026. PMID 42441925. https://doi.org/10.1200/JCO-26-01591 (subscription access)

Surgical quality still shapes survival, and new tools aim to make surgery safer

Directly referenced:

54. Annemarie S, et al. "Surgical quality and long-term outcomes in advanced ovarian cancer: a population based registry study from Hamburg, Germany 2014-2024." Arch Gynecol Obstet. October 29, 2026. PMID 42957917. https://doi.org/10.1007/s00404-026-08578-x

55. Fernandes KA, et al. "Predictive Models of Morbidity and Mortality in Gynaecological Cancer Surgery: A Systematic Review." J Clin Med. October 14, 2026. PMID 42941463. https://doi.org/10.3390/jcm15207948

Additional open-access citations:

56. Li W, et al. "A folate receptor-targeted NIR-II probe improves intraoperative imaging and surgery of metastatic ovarian cancer." Sci Adv. October 2, 2026. PMID 42826211. https://doi.org/10.1126/sciadv.aed7722 (folate receptor-targeted imaging probe for surgery, preclinical)

57. Grønningsæter SR, et al. "Normal Tissue Dosimetry of IntraperitonealRa Microparticle Therapy: Data from First-in-Human Studies in Patients with Peritoneal Metastases." J Nucl Med. October 1, 2026. PMID 42562608. https://doi.org/10.2967/jnumed.125.271925 (intraperitoneal radium-224 microparticle dosimetry, first-in-human)

58. Floru S, et al. "Validation of a Highly Specific Anti-Human Folate Receptor Alpha Single-Domain Antibody for Rapid Fluorescence-Guided Surgery of Ovarian and Lung Cancer." Biomolecules. October 1, 2026. PMID 42939681. https://doi.org/10.3390/biom16101426 (anti-folate receptor alpha single-domain antibody for fluorescence-guided surgery)

Related citations, access restricted:

59. Schoenen S, et al. "Advanced ovarian cancer in women aged ≥80 years: a retrospective single-center study." Eur J Surg Oncol. October 19, 2026. PMID 42913190. https://doi.org/10.1016/j.ejso.2026.112328 (subscription access)

60. Hu G, et al. "Beyond feasibility: an oncology-first framework for defining the role of robot-assisted surgery in ovarian cancer-patient selection, surgical adequacy, and conversion pathways." J Robot Surg. October 12, 2026. PMID 42860479. https://doi.org/10.1007/s11701-026-04020-1 (subscription access)

61. Yang G, et al. "Laparoscopic Versus Laparotomy for Cytoreductive Surgery in Advanced Ovarian Cancer: A Prospective Cohort Study Comparing Surgical Outcomes, Postoperative Complications, Quality of Life, and Survival." J Obstet Gynaecol Res. October 2026. PMID 42896903. https://doi.org/10.1111/jog.70516 (subscription access)

62. Marchetti C, et al. "Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer." JCO Oncol Pract. October 2026. PMID 41284952. https://doi.org/10.1200/OP-25-00469 (subscription access)

63. Dayan-Schwartz A, et al. "Secondary Cytoreduction for Isolated Infra-Renal Para-Aortic Recurrence of High-Grade Serous Ovarian Carcinoma: A Robotic Approach." J Minim Invasive Gynecol. October 2026. PMID 41690457. https://doi.org/10.1016/j.jmig.2026.02.020 (subscription access)

64. Carbonell-Morote S, et al. "Textbook outcome in ovarian cancer with peritoneal carcinomatosis: a systematic review." Clin Transl Oncol. October 2026. PMID 42060080. https://doi.org/10.1007/s12094-026-04378-6 (subscription access)

Hereditary risk and prevention decisions are becoming more personalized

Directly referenced:

65. Gootzen TA, et al. "International trends in concurrent hysterectomy at risk-reducing surgery in BRCA1/2 pathogenic variant carriers: a mixed-methods study." Am J Obstet Gynecol. October 2026. PMID 42323120. https://doi.org/10.1016/j.ajog.2026.06.017

66. Krückel A, et al. "Moderate-risk variants in hereditary breast and ovarian cancer: seven-year experience from a specialized center." Fam Cancer. October 15, 2026. PMID 42878904. https://doi.org/10.1007/s10689-026-00609-5

67. Mayta-Tovalino F, et al. "Talc Use and Risk of Cancer: An Umbrella Review and Overlapped Analysis." Cancer Rep (Hoboken). October 2026. PMID 42833996. https://doi.org/10.1002/cnr2.70705

Additional open-access citations:

68. Alay MT, et al. "HBOCpred: An Ensemble Framework for Prioritisation of Germline Missense Variants in Hereditary Breast and Ovarian Cancer." Int J Mol Sci. October 5, 2026. PMID 42884108. https://doi.org/10.3390/ijms27198865 (computational tool for classifying hereditary variants)

Related citations, access restricted:

69. American College of Obstetricians and Gynecologists. "ACOG Clinical Practice Update: Salpingectomy for the Prevention of Epithelial Ovarian Cancer." Obstet Gynecol. October 2026. PMID 42623672. https://doi.org/10.1097/AOG.0000000000006400 (subscription access)

70. Nam SY, et al. "Age-specific and menopause-specific associations between BMI change and the risk of cervical and ovarian cancers: a population-based cohort study." Menopause. October 1, 2026. PMID 42012837. https://doi.org/10.1097/GME.0000000000002767 (subscription access)

71. Gopal S. "Bridging the BRCA1/2 variant previvor gap in health care." JAAPA. October 2026. PMID 42779039. https://doi.org/10.1097/01.JAA.0000000000000423 (subscription access)

72. Breen KE, et al. "Cancer risks associated with BRCA1 and BRCA2: Overview and management." Cancer. October 15, 2026. PMID 42875977. https://doi.org/10.1002/cncr.70635 (subscription access)

73. Canchi Sistla H, et al. "Evaluation of FGFR2, VEGFA, and MMP1 gene variants for ovarian cancer susceptibility among South Indian women: a hospital-based case-control study." Mol Biol Rep. October 25, 2026. PMID 42927554. https://doi.org/10.1007/s11033-026-13003-2 (subscription access)

74. Tomozawa C, et al. "Exploring factors that influence patient satisfaction in genetic counseling: a post-hoc qualitative analysis of perceived empathy by patients with hereditary breast and ovarian cancer in Japan." J Community Genet. October 5, 2026. PMID 42831959. https://doi.org/10.1007/s12687-026-00953-0 (free to read, no reuse license)

75. Jolley A, et al. "Fallopian Tube Removal During Non-Gynaecological Intra-Abdominal Surgery: An Opportunity to Prevent High Grade Serous Tubo-Ovarian Cancer." ANZ J Surg. October 2026. PMID 42487564. https://doi.org/10.1111/ans.70880 (subscription access)

76. Lu M, et al. "Genotype-driven variations in lncRNA expression underlie predisposition to high-grade serous ovarian cancer." J Adv Res. October 2026. PMID 41500423. https://doi.org/10.1016/j.jare.2026.01.014 (restricted license, CC BY-NC-ND 4.0)

77. Viau L, et al. "Traffic-Related Air Pollution and the Risk of Invasive and Borderline Epithelial Ovarian Tumors." Cancer Epidemiol Biomarkers Prev. October 1, 2026. PMID 42474266. https://doi.org/10.1158/1055-9965.EPI-26-0435 (subscription access)

78. Devi Krishna RB, et al. "Unravelling Ovarian Cancer: an analysis of the Influence of LRP1 and PAI1 Genetic Variations." Biochem Genet. October 2026. PMID 41729408. https://doi.org/10.1007/s10528-026-11331-3 (subscription access)

79. Delahunty R, et al. "Using Polygenic Risk Scores to Refine Risk and Outcomes in High-grade Serous Ovarian Cancer in Australia." Cancer Epidemiol Biomarkers Prev. October 1, 2026. PMID 42560169. https://doi.org/10.1158/1055-9965.EPI-25-1882 (restricted license, CC BY-NC-ND 4.0)

Researchers are building better ways to find ovarian cancer earlier and tell tumor types apart

Directly referenced:

80. Karlsen NS, et al. "Evaluation of the IOTA ADNEX Model, Two-Step Strategy and RMI in Routine Gynaecologic Care in Denmark and Implications for Implementation: A Prospective Multicenter Cohort Study." BJOG. October 2026. PMID 42036775. https://doi.org/10.1111/1471-0528.70253

81. Rani S, et al. "Extracellular vesicle lipidomics liquid biopsy reveals systemic and tumor microenvironment metabolic reprogramming in ovarian cancer." Mol Oncol. October 7, 2026. PMID 42841346. https://doi.org/10.1002/1878-0261.70327

82. Ciccarone F, et al. "Differentiating high- and low-grade serous ovarian carcinoma using radiomics: a pilot study." Ultrasound Obstet Gynecol. October 2026. PMID 42733285. https://doi.org/10.1002/uog.70331

83. Giusti I, et al. "Extracellular vesicles in ovarian cancer liquid biopsy: Advances, challenges, and clinical potential." Crit Rev Oncol Hematol. October 2026. PMID 42362074. https://doi.org/10.1016/j.critrevonc.2026.105456

Additional open-access citations:

84. Ayache K, et al. "Circulating miRNAs and Multivariate Biomarker Signatures in Ovarian Cancer: A Systematic Review." Int J Mol Sci. October 2, 2026. PMID 42884066. https://doi.org/10.3390/ijms27198823 (circulating microRNA biomarkers, systematic review)

85. Cooper N, et al. "Diagnostic imaging of adnexal lesions in pregnancy: systematic review." Ultrasound Obstet Gynecol. October 2026. PMID 42576475. https://doi.org/10.1002/uog.70296 (imaging adnexal masses in pregnancy, systematic review)

86. Saleem MS, et al. "Differential sparse attention framework for accurate ovarian cancer subtype classification using DenseNet121." Front Digit Health. October 8, 2026. PMID 42922966. https://doi.org/10.3389/fdgth.2026.1875306 (deep learning subtype classification from pathology images)

87. Kozłowski M, et al. "Exploratory Analysis of Selected MicroRNAs as Tissue-Based Candidate Biomarkers in Ovarian Cancer." Int J Mol Sci. October 15, 2026. PMID 42941892. https://doi.org/10.3390/ijms27209122 (tissue microRNA biomarkers, exploratory)

88. Alwazzan A, et al. "Tumor Marker Heterogeneity in Ovarian Cancer: Clinical Implications of Pretreatment Monitoring of Serum Biomarkers for Recurrence Prediction." World J Oncol. October 2026. PMID 42730173. https://doi.org/10.14740/wjon2800 (tumor marker patterns before treatment)

Related citations, access restricted:

89. Zhang D, et al. "[Comparison of clinical, imaging, pathological and serological characteristics between appendiceal and ovarian mucinous tumors and analysis of causes of misdiagnosis]." Zhonghua Zhong Liu Za Zhi. October 23, 2026. PMID 42927950. https://doi.org/10.3760/cma.j.cn112152-20260209-00085 (license unconfirmed)

90. Deng Y, et al. "A one-step electrochemical strategy for rapid exosome detection using Cu-coordinated DNA nanoparticles." Biosens Bioelectron. October 2026. PMID 42214850. https://doi.org/10.1016/j.bios.2026.118878 (subscription access)

91. Wang J, et al. "Dual-mode lateral flow immunoassay based on gold nanoparticle-fluorescent microsphere nanocomposites for sensitive CA-125 detection in ovarian cancer screening." Anal Chim Acta. October 2026. PMID 42508911. https://doi.org/10.1016/j.aca.2026.345814 (subscription access)

92. Bi Q, et al. "Foundation Model-empowered Multimodal Prediction of Platinum Resistance in High-grade Serous Ovarian Cancer: A Multicenter Retrospective Study." Acad Radiol. October 2026. PMID 42469040. https://doi.org/10.1016/j.acra.2026.06.024 (subscription access)

93. Sakthivel R, et al. "growth of MoSon MOF-derived ZnSe-FeSefor enhanced charge transfer toward electrochemical immunosensing of the ovarian cancer biomarker CA-125." J Mater Chem B. October 7, 2026. PMID 42755690. https://doi.org/10.1039/d6tb01096b (subscription access)

94. Aastrup M, et al. "Hyperpolarized [1-13C]-Pyruvate MRI Differentiates Benign Fibroma From High-grade Serous Carcinoma." Clin Nucl Med. October 2026. PMID 42714199. https://doi.org/10.1097/RLU.0000000000006625 (subscription access)

95. Leng X, et al. "Liquid biopsy for early detection and biomarker applications in gynecological cancers: current status and future directions." Clin Chim Acta. October 3, 2026. PMID 42829044. https://doi.org/10.1016/j.cca.2026.122873 (subscription access)

96. Jha P, et al. "Screening for Common Gynecologic Malignancies." Radiographics. October 2026. PMID 42821448. https://doi.org/10.1148/rg.260031 (subscription access)

97. Sun Y, et al. "Transforming adnexal mass assessment: how large language model improve ovarian-adnexal reporting and data system interpretation and sonographer performance." Abdom Radiol (NY). October 2026. PMID 41999424. https://doi.org/10.1007/s00261-026-05498-x (subscription access)

98. Pei H, et al. "Triple-Encoding Platform for Multiplexed In Situ Profiling of Extracellular Vesicle miRNAs Enables Precision Diagnosis of Ovarian Cancer." ACS Nano. October 27, 2026. PMID 42937557. https://doi.org/10.1021/acsnano.6c12452 (subscription access)

99. Kittle HD, et al. "Use of Radiographic Features for Risk Stratification of Ovarian Masses in Children and Adolescents." J Surg Res. October 2026. PMID 42537555. https://doi.org/10.1016/j.jss.2026.07.002 (subscription access)

Rare ovarian cancer types are getting more targeted attention

Directly referenced:

100. Grisham RN, et al. "Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201." Gynecol Oncol. October 2026. PMID 42748602. https://doi.org/10.1016/j.ygyno.2026.09.003

101. Schneider DT, et al. "Ovarian Sex Cord Stromal Tumors in Children and Adolescents-The European Standard Clinical Practice Recommendations." Pediatr Blood Cancer. October 2026. PMID 42504512. https://doi.org/10.1002/1545-5017.70571

102. Towery EA, et al. "Serous borderline tumor progressing to low-grade serous carcinoma after 35 years: a case of extended latency with molecular evidence of clonal relationship." Gynecol Oncol Rep. October 2026. PMID 42699673. https://doi.org/10.1016/j.gore.2026.102194

103. Li P, et al. "Primary tubal choriocarcinoma with extrauterine implantation masquerading as ectopic pregnancy: A case report and literature review." Medicine (Baltimore). October 23, 2026. PMID 42937749. https://doi.org/10.1097/MD.0000000000051163

Additional open-access citations:

104. Ito Y, et al. "CEP-1347 Enhances the Sensitivity of Ovarian Clear Cell Carcinoma Cells to Navitoclax by Downregulating MCL1." Int J Mol Sci. October 19, 2026. PMID 42942036. https://doi.org/10.3390/ijms27209261 (navitoclax sensitization in clear cell carcinoma, preclinical)

Related citations, access restricted:

105. Tsang M, et al. "Assessment of delta-like ligand 3 (DLL3) immunostaining in neuroendocrine tumors of the gynecological tract and comparing expression with other high-grade gynecological malignancies." Ann Diagn Pathol. October 2026. PMID 42172687. https://doi.org/10.1016/j.anndiagpath.2026.152664 (subscription access)

106. Wang J, et al. "Clinical and Ultrasound Features of Ovarian Sertoli-Leydig Cell Tumors: A Case Series and Literature Review." J Clin Ultrasound. October 2026. PMID 42204407. https://doi.org/10.1002/jcu.70281 (subscription access)

107. Zhao J, et al. "Clinicopathologic and molecular characterization of uterine and ovarian mixed yolk sac tumor and carcinoma/carcinosarcoma: implications for somatic derivation and therapeutics." Virchows Arch. October 2026. PMID 41563443. https://doi.org/10.1007/s00428-026-04401-9 (subscription access)

108. De Tommasi O, et al. "Current perspectives on targeted and combination pharmacotherapy for low-grade serous ovarian cancer." Expert Opin Pharmacother. October 18, 2026. PMID 42886504. https://doi.org/10.1080/14656566.2026.2749642 (subscription access)

109. Lin CY, et al. "E-cadherin-driven interleukin-6 expression promotes autophagy-mediated platinum resistance in ovarian clear cell carcinoma." Cancer Gene Ther. October 2026. PMID 42632866. https://doi.org/10.1038/s41417-026-01074-z (subscription access)

110. Kim S, et al. "Generalized edema as the initial manifestation of Anti-TIF1γ-positive dermatomyositis associated with ovarian cancer." Neuromuscul Disord. October 9, 2026. PMID 42906361. https://doi.org/10.1016/j.nmd.2026.107452 (subscription access)

111. Liu S, et al. "Histotype and molecular subtype integration in epithelial ovarian cancer: implications for targeted treatment." Cancer Metastasis Rev. October 17, 2026. PMID 42891872. https://doi.org/10.1007/s10555-026-10385-4 (restricted license, CC BY-NC-ND 4.0)

112. Grisham RN, et al. "Low-grade serous ovarian cancer: 2026 expert consensus report." Gynecol Oncol. October 22, 2026. PMID 42913278. https://doi.org/10.1016/j.ygyno.2026.10.011 (restricted license, CC BY-NC-ND 4.0)

113. Huang S, et al. "Morphologic, immunohistochemical, and preliminary molecular findings of primary ovarian carcinoid tumors in a tertiary center cohort." Pathol Res Pract. October 2026. PMID 42269538. https://doi.org/10.1016/j.prp.2026.156584 (subscription access)

114. Zadeh T, et al. "Mucinous Adenocarcinoma Arising in a Mature Ovarian Teratoma." R I Med J (2013). October 1, 2026. PMID 42789804. https://pubmed.ncbi.nlm.nih.gov/42789804/ (license unconfirmed)

115. Fujiyama K, et al. "Myotonic dystrophy type 1 as a cancer predisposition syndrome: A case report of quadruple primary malignancies with review of the literature." Gynecol Oncol Rep. October 1, 2026. PMID 42890353. https://doi.org/10.1016/j.gore.2026.102228 (restricted license, CC BY-NC-ND 4.0)

116. Harsh P, et al. "Paraneoplastic Cerebellar Degeneration Presenting as Subacute Ataxia with Normal Neuroimaging: A Diagnostic Challenge." Ann Afr Med. October 2026. PMID 42458979. https://doi.org/10.4103/aam.aam_454_26 (restricted license, CC BY-NC-ND 4.0)

117. Alcheikh R, et al. "Pediatric lynch-associated melanoma arising in ovarian teratoma: a case report." Gynecol Oncol Rep. October 3, 2026. PMID 42923311. https://doi.org/10.1016/j.gore.2026.102226 (restricted license, CC BY-NC-ND 4.0)

118. Yu C, et al. "Proteomic Landscape and Clinical Implications of Ovarian Carcinosarcoma." FASEB J. October 31, 2026. PMID 42886654. https://doi.org/10.1096/fj.202503966R (subscription access)

119. Zacholski EH, et al. "Response to Sotorasib in a patient with recurrent KRAS G12C-mutated low-grade serous ovarian cancer: a case report and literature review." Gynecol Oncol Rep. October 2026. PMID 42756523. https://doi.org/10.1016/j.gore.2026.102203 (restricted license, CC BY-NC-ND 4.0)

120. Xu Y, et al. "Targeting PI3Kγ/AKT1-OCT4/SOX2 axis with eganelisib suppresses tumor growth and prevents ovarian failure in malignant ovarian germ cell tumors." Int J Biochem Cell Biol. October 2026. PMID 42288209. https://doi.org/10.1016/j.biocel.2026.106987 (restricted license, CC BY-NC-ND 4.0)

Support, communication, and nursing care matter throughout treatment

Directly referenced:

121. Yates P, et al. "Optimising ovarian cancer care: An embedded mixed methods evaluation of a national nurse-led telehealth program." Support Care Cancer. October 7, 2026. PMID 42839062. https://doi.org/10.1007/s00520-026-11284-8

122. de Vries S, et al. "How patients with advanced gynecological cancer perceive clinicians' attention to their values, wishes, and needs: a qualitative study." Patient Educ Couns. October 28, 2026. PMID 42966078. https://doi.org/10.1016/j.pec.2026.110371

123. Williams N, et al. "Shaping Specialized Gynecological Cancer Nursing Guidance: A Cross Sectional Study Identifying Implementation Determinants." Semin Oncol Nurs. October 12, 2026. PMID 42863281. https://doi.org/10.1016/j.soncn.2026.152402

Related citations, access restricted:

124. Wang Y, et al. "From data to personas: a multi-source approach to tailored online health information recommendation for ovarian cancer patients and caregivers." J Am Med Inform Assoc. October 18, 2026. PMID 42893544. https://doi.org/10.1093/jamia/ocag169 (subscription access)

125. İnan M, et al. "The Invisible Workforce: An Algorithmic Audit of Nursing, Primary Care, and Holistic Gaps in AI-Generated Survivorship Plans." Semin Oncol Nurs. October 2026. PMID 42608279. https://doi.org/10.1016/j.soncn.2026.152304 (subscription access)

Epidemiology, access, and health disparities research shows where gaps remain

Directly referenced:

126. Meagher NS, et al. "Differences in overall survival for invasive epithelial ovarian cancer by race and ethnicity: results from the Ovarian Cancer Association Consortium." Br J Cancer. October 2026. PMID 42373846. https://doi.org/10.1038/s41416-026-03509-8

127. O'Connor RM, et al. "Association of community-level social vulnerability with county-level clinical trial access among ovarian cancer patients." Gynecol Oncol. October 2026. PMID 42771918. https://doi.org/10.1016/j.ygyno.2026.09.007

128. Tan C, et al. "Impact of the COVID-19 pandemic on diagnosis, treatment, and prognosis of cervical, endometrial, and ovarian cancers: A retrospective cohort study based on the SEER database." Medicine (Baltimore). October 16, 2026. PMID 42888541. https://doi.org/10.1097/MD.0000000000051038

Related citations, access restricted:

129. Bates N, et al. "Distance From Residence to Hospital and Mortality Among Patients Diagnosed With and Receiving Surgical Treatment for Late-Stage Epithelial Ovarian Cancer in the United States." J Obstet Gynaecol Res. October 2026. PMID 42849902. https://doi.org/10.1111/jog.70517 (subscription access)

General and basic-science research continues to probe how ovarian tumors grow and resist treatment

Additional open-access citations:

130. Chabowska G, et al. "A Novel 2,7-Naphthyridine Derivative Suppresses Ovarian Cancer Cell Growth Through G1 Cell Cycle Arrest, Apoptosis Induction and Migration Inhibition." Pharmaceuticals (Basel). October 1, 2026. PMID 42943259. https://doi.org/10.3390/ph19101562 (naphthyridine derivative, preclinical)

131. Merecz-Sadowska A, et al. "Celastrol and Its Derivatives in Breast, Ovarian, and Cervical Cancer: Molecular Targets, Signalling Networks, and Nanocarrier-Based Delivery." Molecules. October 12, 2026. PMID 42943713. https://doi.org/10.3390/molecules31203641 (celastrol in breast, ovarian, and cervical cancer, review)

132. Li W, et al. "Characterizing intra- and intertumor heterogeneity in ovarian high-grade serous carcinoma subtypes using single-cell and spatial transcriptomics." Genome Res. October 1, 2026. PMID 42608147. https://doi.org/10.1101/gr.281433.125 (single-cell heterogeneity across subtypes)

133. Guilbard M, et al. "Complementary intra- and extracellular AGR2 activities support epithelial ovarian cancer cell aggressiveness." Oncogene. October 2026. PMID 42575981. https://doi.org/10.1038/s41388-026-03938-y (AGR2 and tumor aggressiveness)

134. Karageçili S, et al. "Computational identification of natural CXCR4-binding candidates relevant to endometriosis and ovarian cancer progression." PLoS One. October 7, 2026. PMID 42842599. https://doi.org/10.1371/journal.pone.0359833 (computational CXCR4 binders)

135. Ma Y, et al. "Deubiquitinase USP38 Stabilizes PLK1 Expression to Boost DNA Damage Repair in Ovarian Cancer." Kaohsiung J Med Sci. October 2026. PMID 41854204. https://doi.org/10.1002/kjm2.70197 (USP38 and PLK1 in DNA repair)

136. Pașca A, et al. "Distinct sFOLR1 and Cytokine Secretion Profiles Across Marker-Enriched OVCAR-3 Ovarian Cancer Cell Subpopulations: A Pilot Study." Biomolecules. October 7, 2026. PMID 42939716. https://doi.org/10.3390/biom16101462 (OVCAR-3 subpopulation secretion profiles)

137. Dumbrava MG, et al. "Epigenetic adaptations and vulnerabilities in ovarian cancer drug-tolerant persister cells." NAR Cancer. October 22, 2026. PMID 42923094. https://doi.org/10.1093/narcan/zcag030 (drug-tolerant persister cells, review)

138. Panneerdoss DM, et al. "ERX-208 Induces Endoplasmic Reticulum Stress and Suppresses DNA Damage Repair to Enhance Chemotherapy Sensitivity." Cancer Res Commun. October 1, 2026. PMID 42842296. https://doi.org/10.1158/2767-9764.CRC-26-0421 (ERX-208 and chemotherapy sensitivity, preclinical)

139. Piegat A, et al. "Evaluation of Modified Chitosan Nanomicelles with Carboplatin for Effective Treatment Against Ovarian Cancer Cell Types in Murine Model." Int J Nanomedicine. October 12, 2026. PMID 42892969. https://doi.org/10.2147/IJN.S634858 (carboplatin nanomicelles, preclinical)

140. Xing Y, et al. "Ferroptosis and nutrient-metabolic pathway genes in ovarian cancer: integrated bulk and single-cell analysis of Iron-metabolic programs, immune-marker enrichment, and prognosis." Front Public Health. October 2, 2026. PMID 42890305. https://doi.org/10.3389/fpubh.2026.1967476 (ferroptosis and metabolic gene signatures)

141. Gao M, et al. "H3K18la Facilitates TRA2A-Mediated Alternative Splicing of STIL, Suppressing Ferroptosis and Cisplatin Treatment Sensitivity in Ovarian Cancer." Cancer Res Treat. October 2026. PMID 40907573. https://doi.org/10.4143/crt.2025.752 (H3K18 lactylation and cisplatin sensitivity)

142. Levy D. "Incorporating Lesion-Level Heterogeneity in a Branching-Process Model of Ovarian Cancer Metastasis." Bull Math Biol. October 21, 2026. PMID 42905339. https://doi.org/10.1007/s11538-026-01772-7 (mathematical model of metastasis)

143. Jiang W, et al. "Integrative Multi-Omics Analysis Reveals a Mitochondrial-Immune Axis Associated With Neoadjuvant Chemotherapy Response in High-Grade Serous Ovarian Cancer." Adv Sci (Weinh). October 2026. PMID 42474029. https://doi.org/10.1002/advs.202523029 (mitochondrial-immune axis and neoadjuvant response)

144. Leng W, et al. "Integrative Multi-Omics and Experimental Validation Define RELB as an Immune-Related Prognostic Driver in Ovarian Cancer." Chem Biol Drug Des. October 2026. PMID 42870286. https://doi.org/10.1111/cbdd.70409 (RELB as a prognostic driver)

145. An C, et al. "Mechanical dysfunction: ovarian cancer ascites disables NK cells by suppressing CDC42-driven force generation." Front Immunol. October 16, 2026. PMID 42964141. https://doi.org/10.3389/fimmu.2026.1883517 (ascites and NK cell mechanics)

146. Gao Y, et al. "Mitochondrial SLC25A46 Rewires Fatty Acid Oxidation to Promote Cell Proliferation and Ferroptosis Evasion in Ovarian Cancer by Stabilizing CACT." Adv Sci (Weinh). October 2026. PMID 42474085. https://doi.org/10.1002/advs.202523969 (SLC25A46 and fatty acid oxidation)

147. Paberalė E, et al. "Monocyte-derived dendritic cell activation is broadly conserved across immune phenotype-specific ovarian tumor lysate pools, with donor-associated variation in response magnitude." J Leukoc Biol. October 5, 2026. PMID 42885837. https://doi.org/10.1093/jleuko/qiag134 (dendritic cell activation by tumor lysates)

148. Qian J, et al. "Multi-omics analysis of high-grade serous ovarian cancers reveals heterogeneity and distinct immunological patterns based upon clinico-genomic status." PLoS Genet. October 22, 2026. PMID 42911976. https://doi.org/10.1371/journal.pgen.1012355 (multi-omics of high-grade serous cancers)

149. Zhao Y, et al. "Multi-Omics Profiling of High-Grade Serous Ovarian Cancer Reveals an Inflammation-Related Lipid Metabolism Subtype Associated With Platinum Resistance." Adv Sci (Weinh). October 2026. PMID 42466711. https://doi.org/10.1002/advs.76482 (lipid metabolism subtype of high-grade serous cancer)

150. de Souza-Araújo CN, et al. "Ovarian Cancer-Associated Ascites Accumulates NK Lymphocytes Displaying a Transcriptomic Profile Consistent With the Immature/Secretory CD56Subtype." Immunol Cell Biol. October 2026. PMID 42619603. https://doi.org/10.1111/imcb.70159 (NK cells in ascites)

151. Pereira GBS, et al. "Phototoxicity evaluation of tetra-cationic ruthenium-arene-phosphine porphyrins in ovarian tumor cells." Biomater Adv. October 2026. PMID 42184710. https://doi.org/10.1016/j.bioadv.2026.214953 (photodynamic porphyrins, preclinical)

152. Hell L, et al. "Plasticity and immune marker profiling of tumour- and ascites-derived microtumours in serous ovarian cancer: relevance for short-term culture models." Front Immunol. October 7, 2026. PMID 42909065. https://doi.org/10.3389/fimmu.2026.1901291 (tumor and ascites microtumor immune profiling)

153. Mousavi Z, et al. "Preparation and Characterization of Ocimum basilicum Extract-Loaded Niosomes and Evaluation of Their Cytotoxic and Pro-Apoptotic Potential in SKOV3 Ovarian Cancer Cells." Chem Biodivers. October 2026. PMID 42809506. https://doi.org/10.1002/cbdv.71779 (basil extract niosomes, preclinical)

154. Li H, et al. "Quercetin induces ferroptosis in ovarian cancer by suppressing the NRF2/HO‑1/GPX4 axis and increasing the efficacy of cisplatin." Biochem Pharmacol. October 2026. PMID 42456829. https://doi.org/10.1016/j.bcp.2026.118263 (quercetin and ferroptosis, preclinical)

155. Polchai N, et al. "Retrospective assessment of TCF12 expression in early invasive breast cancer and ovarian cancer: prognostic implications and biological insights." Pathology. October 2026. PMID 42552187. https://doi.org/10.1016/j.pathol.2026.05.009 (TCF12 expression and prognosis in breast and ovarian cancer)

156. Mao Y, et al. "Selective Depletion of Tumor-Infiltrating CD4CCR8Tregs by AZ084, a Novel CCR8 Antagonist." Cancer Sci. October 2026. PMID 42437746. https://doi.org/10.1111/cas.70465 (CCR8 antagonist depleting regulatory T cells, preclinical)

157. Mohiuddin TM, et al. "Tissue Factor Expression Is Associated with Distinct Pattern of Immune-Cell Infiltration in the Ovarian Tumor Microenvironment." Int J Mol Sci. October 15, 2026. PMID 42941916. https://doi.org/10.3390/ijms27209148 (tissue factor and immune infiltration)

158. Kruse S, et al. "Tumor-specific super-enhancer drives overexpression of EVI1/MECOM in ovarian cancer." Neoplasia. October 12, 2026. PMID 42863188. https://doi.org/10.1016/j.neo.2026.101380 (EVI1/MECOM super-enhancer)

159. Chao WT, et al. "α2,3-Sialyltransferase (ST3Gal1) regulates endometrioid-type epithelial ovarian cancer cell migration and invasion via VEGF-R2/JAK2/STAT3 signaling cascades." Int J Gynaecol Obstet. October 2026. PMID 42080626. https://doi.org/10.1002/ijgo.71057 (ST3Gal1 in endometrioid ovarian cancer)

Related citations, access restricted:

160. Pan Z, et al. "A Platinum(IV)-Ursolic Acid Conjugate Overcomes Cisplatin Resistance in Ovarian Cancer by Targeting XPO1 and PARP1." J Med Chem. October 8, 2026. PMID 42917917. https://doi.org/10.1021/acs.jmedchem.6c02041 (subscription access)

161. Du H, et al. "Adiponectin receptor agonist AdipoRon induces autophagy via AdipoR1/2-AMPK pathway and suppresses tumor progression in ovarian cancer." Naunyn Schmiedebergs Arch Pharmacol. October 2026. PMID 42414696. https://doi.org/10.1007/s00210-026-05669-z (subscription access)

162. Sun Y, et al. "AI-driven transformer-guided fragment-based discovery of Prostaglandin A1 as a multi-target inhibitor of PSAT1, PARP1, and PIK3CA in ovarian cancer." Comput Biol Chem. October 2026. PMID 42288105. https://doi.org/10.1016/j.compbiolchem.2026.109156 (subscription access)

163. Zhang H, et al. "Bisphenol A exposure confers resistance to cisplatin in ovarian cancer via ERα-dependent DDIT4-mTOR-AKT signaling." J Hazard Mater. October 2026. PMID 42767054. https://doi.org/10.1016/j.jhazmat.2026.143666 (subscription access)

164. Cao L, et al. "CDS2 Drives Tumor Progression in Epithelial Ovarian Cancer via the PI3K/AKT Pathway." Cancer Med. October 2026. PMID 42897435. https://doi.org/10.1002/cam4.72309 (restricted license, CC BY-NC-ND 4.0)

165. Chatterjee DR, et al. "Coumarin-sulfonamide hybrids as PKM2 activators induce metabolic reprogramming and suppress ovarian cancer cell growth." Bioorg Med Chem. October 2026. PMID 42372628. https://doi.org/10.1016/j.bmc.2026.118733 (subscription access)

166. Esmaeli M, et al. "Curcumin in ovarian cancer: mechanistic insights and translational potential." Med Oncol. October 9, 2026. PMID 42853302. https://doi.org/10.1007/s12032-026-03454-9 (subscription access)

167. Hu YB, et al. "Deep Learning of Position-Aligned Dynamic Cell Deformation Trajectories for Ovarian Cell Phenotyping in Hyperbolic Microchannels." Anal Chem. October 27, 2026. PMID 42937350. https://doi.org/10.1021/acs.analchem.6c05067 (restricted license, CC BY-NC-ND 4.0)

168. Dessai PG, et al. "Design, Synthesis, and Biological Evaluation of Quinolin-2-One-Indole Schiff Base Hybrids as Potential EGFR-Targeted Anticancer Agents Against Breast and Ovarian Cancer." ChemMedChem. October 28, 2026. PMID 42897752. https://doi.org/10.1002/cmdc.70541 (subscription access)

169. Qi H, et al. "Discovery of 4-Aminoquinazoline Derivatives as Potent PKMYT1 Inhibitors via Hydrogen Bond Donor-To-Acceptor Conversion for CCNE1-Amplified Cancers." J Med Chem. October 22, 2026. PMID 42911706. https://doi.org/10.1021/acs.jmedchem.6c01446 (subscription access)

170. Cai S, et al. "Discovery of a Novel Dual Inhibitor Targeting Tubulin and Histone Deacetylase 8 for Treatment of the Ovarian Cancer." J Med Chem. October 22, 2026. PMID 42911747. https://doi.org/10.1021/acs.jmedchem.6c01002 (subscription access)

171. Mukai K, et al. "Discovery of INCB127443: A Potent and Orally Available Inhibitor of Cyclin-Dependent Kinase 2." J Med Chem. October 22, 2026. PMID 42911678. https://doi.org/10.1021/acs.jmedchem.6c01506 (subscription access)

172. Alzu'bi A, et al. "Dose-dependent CXCR4 inhibition in ovarian cancer cellular models reveals a paradoxical response characterized by subtype-specific oncogenic suppression and stress-induced adaptive rebound." Mol Biol Rep. October 16, 2026. PMID 42886399. https://doi.org/10.1007/s11033-026-12917-1 (subscription access)

173. Ma Y, et al. "Expression of V‑domain Ig suppressor of T cell activation in ovarian cancer and its regulation of follicular regulatory T‑cell function via the AKT/MAPK pathway." Oncol Rep. October 9, 2026. PMID 42852629. https://doi.org/10.3892/or.2026.9206 (restricted license, CC BY-NC-ND 4.0)

174. Anika UL, et al. "Histopathological and Bioinformatic Analysis of the IL-6/STAT3 Signaling Pathway in Ovarian Neoplasms." Pak J Biol Sci. October 2026. PMID 42831402. https://doi.org/10.3923/pjbs.2026.341.350 (license unconfirmed)

175. Tu XM, et al. "Integrated Network Pharmacology and Proteomics Reveal Anti-tumor Mechanism of Securinine in Ovarian Cancer." Chin J Integr Med. October 2026. PMID 42448946. https://doi.org/10.1007/s11655-026-4246-1 (subscription access)

176. Zhao R, et al. "KAZALD1 upregulation predicts poor prognosis in epithelial ovarian cancer: Clinical validation and immune correlates." Oncol Lett. October 15, 2026. PMID 42935823. https://doi.org/10.3892/ol.2026.15908 (restricted license, CC BY-NC-ND 4.0)

177. Stirblyte K, et al. "Lipid metabolism in γδ T-cell activation: Implications for immunotherapy in ovarian cancer." Transl Oncol. October 2026. PMID 42520474. https://doi.org/10.1016/j.tranon.2026.102953 (restricted license, CC BY-NC-ND 4.0)

178. Wang T, et al. "LOX-1 mediated lipid peroxidation leads to dysfunction of tumor infiltrating CD8T cells in ovarian cancer." Redox Biol. October 2026. PMID 42537477. https://doi.org/10.1016/j.redox.2026.104311 (restricted license, CC BY-NC-ND 4.0)

179. Guo X, et al. "Metabolic vulnerabilities in ovarian cancer decoding the nexus between nutrient adaptation and therapy resistance." J Adv Res. October 2026. PMID 41558606. https://doi.org/10.1016/j.jare.2026.01.047 (restricted license, CC BY-NC-ND 4.0)

180. Shin MJ, et al. "MHY5535, a novel PPARα antagonist, sensitizes ovarian cancer stem cells to chemotherapy by disrupting fatty acid oxidation-dependent mitochondrial metabolism." Biomed Pharmacother. October 2026. PMID 42585815. https://doi.org/10.1016/j.biopha.2026.119842 (restricted license, CC BY-NC-ND 4.0)

181. Chen X, et al. "Modulating the gut-reproductive tract axis: microbial influence on gynaecological cancer pathogenesis and treatment." Gut. October 7, 2026. PMID 41667242. https://doi.org/10.1136/gutjnl-2025-337778 (subscription access)

182. Long W, et al. "Natural killer cells in ovarian cancer therapy: mechanisms, evasion, and therapeutic innovations." Inflammopharmacology. October 2026. PMID 42753071. https://doi.org/10.1007/s10787-026-02397-x (subscription access)

183. Cui G, et al. "NCAPD2 facilitates ovarian cancer progression via MYC-mediated unfolded protein response." Biochim Biophys Acta Mol Cell Res. October 2026. PMID 42586216. https://doi.org/10.1016/j.bbamcr.2026.120209 (subscription access)

184. Thirusangu P, et al. "Nuclear cathepsin L induces DNA damage by regulating DNA repair factors in ovarian cancer." Oncogene. October 1, 2026. PMID 42823448. https://doi.org/10.1038/s41388-026-04001-6 (restricted license, CC BY-NC-ND 4.0)

185. Challa S, et al. "PARP16 is a druggable regulator of ribosome MARylation and protein homeostasis in ovarian cancer cells." J Biol Chem. October 2026. PMID 42710679. https://doi.org/10.1016/j.jbc.2026.113540 (restricted license, CC BY-NC-ND 4.0)

186. Zhang H, et al. "PIKfyve-specific Pt(II)-based targeted drug conjugate in treatment of ovarian cancer through multi-mode actions." J Inorg Biochem. October 2026. PMID 42365687. https://doi.org/10.1016/j.jinorgbio.2026.113398 (subscription access)

187. Kirmuć J, et al. "Platelet activation and eicosanoid signaling in ovarian cancer: implications for biomarker development." Mol Biol Rep. October 1, 2026. PMID 42821018. https://doi.org/10.1007/s11033-026-12848-x (restricted license, CC BY-NC-ND 4.0)

188. Yang J, et al. "Polymeric nanoparticle gene delivery to reprogram the tumor immune microenvironment in ovarian cancer for an anti-tumor response." Acta Biomater. October 16, 2026. PMID 42887583. https://doi.org/10.1016/j.actbio.2026.10.029 (restricted license, CC BY-NC-ND 4.0)

189. Farahmandpour S, et al. "Preparation and characterization of Kaempferol-loaded Niosomes and their effects on apoptosis and cell migration in SKOV3 ovarian cancer cells." Mol Biol Rep. October 25, 2026. PMID 42927538. https://doi.org/10.1007/s11033-026-12981-7 (subscription access)

190. Rasouli A, et al. "Repurposing Entrectinib and Ibrutinib as MNK/eIF4E pathway modulators in ovarian cancer." Eur J Pharmacol. October 17, 2026. PMID 42892507. https://doi.org/10.1016/j.ejphar.2026.179438 (subscription access)

191. Gong L, et al. "Selective anticancer activity of a multinuclear Cu(II) complex through apoptosis induction in ovarian cancer cells." Bioorg Chem. October 2026. PMID 42648236. https://doi.org/10.1016/j.bioorg.2026.110383 (subscription access)

192. Lee DH, et al. "Sensitizing nanomedicine for platinum-resistant ovarian cancer." Nanomedicine (Lond). October 2026. PMID 42802703. https://doi.org/10.1080/17435889.2026.2738705 (subscription access)

193. Coté JJ, et al. "Serum Interleukin-6 Levels in Endometriosis and Endometriosis-Associated Ovarian Cancer: A Systematic Review and Meta-Analysis Demonstrating a Biological Gradient." J Minim Invasive Gynecol. October 2026. PMID 42323960. https://doi.org/10.1016/j.jmig.2026.06.015 (subscription access)

194. Zheng Y, et al. "Sp1 induces autophagic in epithelial ovarian cancer through inhibition of the PI3K/AKT/mTOR pathway." Tissue Cell. October 2026. PMID 42143415. https://doi.org/10.1016/j.tice.2026.103612 (subscription access)

195. Wang J, et al. "Spatiotemporally Controlled Prodrug Release From Light-Triggered Azo-Bond-Cleaved BODIPY Nanoplatform for Trimodal Synergistic Ovarian Cancer Therapy." Adv Healthc Mater. October 2026. PMID 42649575. https://doi.org/10.1002/adhm.71656 (subscription access)

196. Wang M, et al. "STXBP6-driven signaling cascade alters lipid peroxidation in tumor-associated macrophages to facilitate ovarian cancer progression." Redox Biol. October 2026. PMID 42476006. https://doi.org/10.1016/j.redox.2026.104299 (restricted license, CC BY-NC-ND 4.0)

197. Zhao N, et al. "TAL1 Suppresses High-Grade Serous Ovarian Cancer Progression by Transcriptionally Inhibiting TPI1-Mediated Glycolysis." Tohoku J Exp Med. October 2026. PMID 41638669. https://doi.org/10.1620/tjem.2025.J169 (license unconfirmed)

198. Hadi S, et al. "The biological roles and therapeutic potential of nicotinamide N-methyltransferase in ovarian cancer‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬." Pathol Res Pract. October 2026. PMID 42269537. https://doi.org/10.1016/j.prp.2026.156581 (subscription access)

199. Kharwar A, et al. "Toward FOXM1 inhibitors based on supervised machine learning classification models and similarity-based screening." J Comput Aided Mol Des. October 9, 2026. PMID 42853417. https://doi.org/10.1007/s10822-026-00952-w (subscription access)

200. ALzahrani R, et al. "Translational applications and clinical utility of organoids in ovarian cancer: a systematic review." Cancer Chemother Pharmacol. October 22, 2026. PMID 42911417. https://doi.org/10.1007/s00280-026-04973-y (subscription access)

201. Savenkova D, et al. "Tumorigenic microenvironment alters N-terminal membrane protein topology via a mechanism consistent with the Charge Balance Rule." Biochim Biophys Acta Mol Basis Dis. October 28, 2026. PMID 42951046. https://doi.org/10.1016/j.bbadis.2026.168520 (subscription access)

202. Ren Y, et al. "Verbascoside inhibits ovarian cancer proliferation via IRAK4-CXCL5 axis-mediated suppression of neutrophil infiltration and neutrophil extracellular trap formation." Cancer Lett. October 17, 2026. PMID 42887866. https://doi.org/10.1016/j.canlet.2026.218901 (subscription access)

A note on how this digest was made: This edition was built by searching PubMed for papers published in October 2026, using a two-tier strategy: targeted searches across the ovarian, fallopian tube, and peritoneal cancer landscape (PARP inhibitors, immunotherapy and ADCs, BRCA/HRD and hereditary risk, surgery, platinum resistance, early detection, subtypes, survivorship, and disparities) plus a dedicated qualitative search. Papers summarized in full are open access under a permitted license (CC0, CC BY, CC BY-SA, CC BY-ND, or CC BY-NC); on-topic papers under other licenses are listed by citation only. A companion methodology report, available separately, documents the full search-and-screening process and every paper reviewed.